A PSEN2 genetic test is rarely ordered because dementia symptoms progress. PSEN2 is a gene that helps process amyloid precursor protein, and specific inherited changes in it can cause early-onset Alzheimer's disease.
Worsening memory or function alone does not qualify most people for testing or payment. Testing matters mainly for families with early onset and a strong inheritance pattern. Readers deciding next steps should focus on age at onset, family history, referral path, and written cost terms before agreeing to a sample.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What a PSEN2 test checks
- Does progressing dementia qualify you for testing?
- What will testing cost and will insurance pay?
- How to get the right referral
- When progression still needs urgent attention
What a PSEN2 test checks
PSEN2 gives instructions for making presenilin 2, a protein involved in processing amyloid precursor protein. According to MedlinePlus Genetics, at least 11 PSEN2 mutations cause early-onset Alzheimer's and account for less than 5% of early-onset cases in an autosomal-dominant pattern MedlinePlus PSEN2 gene page. Autosomal-dominant means one copy of the changed gene can pass the risk through generations. PSEN2 is almost never tested alone.
Early-onset Alzheimer's is linked to APP, PSEN1, and PSEN2, so labs usually sequence those genes together. According to the Perelman School of Medicine at the University of Pennsylvania, testing is recommended for patients with at least three affected family members or onset before age 60 Penn Advancing Genomic Medicine page. The same Penn source reports a 5-13% diagnostic yield across APP, PSEN1, and PSEN2 in that selected group. A negative result does not rule out dementia. A positive result points to an inherited cause, not a treatment choice for current symptoms.
Does progressing dementia qualify you for testing?
Progression is distressing, but it is not the main eligibility test. Insurers look for early onset, usually before age 60 or 65, plus family pattern, known familial mutation, or need for specific medical decisions. Late-onset symptoms that worsen after 65 usually point toward clinical care, safety planning, and support services instead. A commercial policy example makes the line clear.
Blue Cross NC policy M2038 treats APP, PSEN1, and PSEN2 testing as medically necessary only in narrow cases tied to reproductive decision-making plus autosomal-dominant family history, a known familial mutation, or symptomatic early-onset disease with unknown family history. Confirmatory diagnosis, testing children, late-onset disease after 65, APOE testing, general risk assessment, and asymptomatic screening are listed as investigational and not covered. That means a reader should document onset age first. Gather ages at diagnosis for parents, siblings, aunts, uncles, and grandparents. Note anyone with dementia before 60, multiple affected relatives, or a known gene change in the family.
What will testing cost and will insurance pay?
There is no single U.S. price because panel breadth, laboratory, and insurance terms differ. One laboratory lists a 35-gene Parkinson-Alzheimer-Dementia panel at $600, while ARUP directs patients to a plan-specific out-of-pocket estimator, according to GeneStreet and ARUP pricing pages GeneStreet Alzheimer's disease listing. Ask whether the quote includes collection, sequencing, interpretation, counseling, and any repeat draw.
Medicare adds another limit. There is no Medicare national coverage determination for Alzheimer genetic testing, so local carriers set rules and often deny payment except in narrow early-onset familial circumstances. Families on Medicare Advantage or commercial plans should get the rule in writing for their own plan. Use these checks before testing:.
- Ask for CPT codes, medical-necessity criteria, and prior authorization in writing.
- Ask for a self-pay quote, payment deadline, and whether counseling is billed separately.
- Ask what happens if coverage is denied after the sample is sent.
How to get the right referral
Start with the doctor managing dementia care, not a direct-to-consumer kit. People with a family history of early-onset Alzheimer's should discuss testing with a doctor, who may first refer them to a genetic counselor to explain risk, benefits, and next steps. Bring a one-page family history, medication list, and prior imaging or cognitive-test results.
ARUP Laboratories offers an early-onset Alzheimer's sequencing panel for people with suspected disease or family history diagnosed before age 65, and it requires a patient history form and informed consent for presymptomatic adult testing ARUP early-onset Alzheimer's test page. A counselor can explain who should be tested first. Often the affected relative with the earliest onset is the most informative person to test. Ask the referral office these exact questions:.
- Should testing start with my affected relative or with me?
- Which genes are included, and why is PSEN2 included or excluded?
- Who will disclose results, and will they enter my medical record?
- If I test positive, what changes for relatives, family planning, work, or long-term care planning?
When progression still needs urgent attention
Genetic results do not explain every change in late-stage dementia. New confusion, falls, incontinence, weight loss, agitation, or loss of daily skills deserve prompt medical review for infection, medication effects, dehydration, pain, depression, sleep apnea, or unsafe home setup. Treat progression as a care problem first.
If early-onset inheritance is possible, pursue genetics and clinical care in parallel. Schedule neurology, primary care, counseling, and caregiver support without waiting for test authorization. Save every referral letter, denial, consent form, and cost estimate in one folder for appeals.
